Emami Q2 FY27: consol PAT flat YoY at ₹146 Cr; tax reset masks 29% PBT growth, OPM slips
PAT -1.92% YoY · revenue +36.21% · margins compressing · miss vs street
₹1,087.65 Cr
+36.21% YoY
₹145.5 Cr
-1.92% YoY
13.1%
-5pp YoY
₹3.3
Emami's consolidated PAT was essentially flat year-on-year at ₹145.5 Cr (-1.9%, the primary comparison) even as revenue rose 36.2% YoY to ₹1,087.65 Cr; sequentially PAT and revenue both grew about 4.7% QoQ. The flat PAT print is misleading on its own: consolidated PBT actually jumped 28.9% YoY to ₹193.6 Cr, and the gap to PAT is a tax base-effect rather than an operating one — Q2 FY26's effective tax rate was an abnormally low 1.2% (helped by a ₹27.4 Cr MAT-credit-utilisation credit), against a normalised ~24.9% (₹48.1 Cr) this quarter. Basic EPS was ₹3.30, versus ₹3.40 a year ago and ₹3.15 last quarter.
Q2 FY-2027 vs prior quarters
Much of the headline revenue growth is inorganic: standalone (core Emami, ex-subsidiaries) revenue grew a slower 15.5% YoY to ₹698.2 Cr, with the gap explained by the April 2026 consolidation of Axiom Ayurveda and the June 2026 consolidation of IncNut Digital as subsidiaries. Operating margin (OPM, EBITDA excluding other income, over revenue) compressed to 20.44% from 22.36% a year ago and 21.76% last quarter, as cost of materials consumed rose 51.7% YoY — well ahead of revenue growth — and finance costs more than doubled to ₹6.08 Cr on acquisition-related borrowings and financial liabilities. Standalone PAT fell 25.2% YoY to ₹136.5 Cr even though standalone PBT was flat (+0.7%), confirming the decline there is the same MAT-credit tax-timing swing rather than weaker core operations.
The stock went into the print at ₹389.3, up 1.4% over the past month of trading.
FY27 strategic investments to reach ₹750–800 Cr (vs ₹160 Q1), growing 20–30% YoY. Core domestic to accelerate beyond 6% as commodity pressure eases and pricing sticks. International to recover Q3–Q4; margin pressure temporary, offset by aggressive price increases and cost controls.
— This quarter: missed
HDFC Securities had modelled Q2 FY27 revenue up roughly 20% YoY and adjusted PAT up roughly 4% YoY; the actual print beat on revenue (+36.2%, aided by the M&A consolidation) but missed on reported PAT (-1.9%). Management's prior concall had guided core domestic growth accelerating past 6% as commodity pressure eased, with margin pressure easing via price hikes and cost control; instead OPM compressed further this quarter, while international revenue stayed flat YoY at ₹182.2 Cr (+1.1%) — management had pointed to a Q3-Q4 recovery there, so this quarter's flatness sits within that stated timeline rather than being a fresh miss. Advertisement and sales-promotion spend rose 37.9% YoY to ₹215.7 Cr, running ahead of the ₹750-800 Cr / 20-30% YoY FY27 strategic-investment band flagged last quarter. Alongside results, the board declared a ₹5/share (500% of face value) first interim dividend (record date 13 November 2026) and the ₹281.24 Cr, 73-lakh-share buyback was confirmed completed and fully extinguished in October.
W1
International revenue was flat YoY (₹182.2 Cr, +1.1%) in Q2 — management guided a recovery in Q3-Q4 FY27; watch for a pickup next quarter.
W2
OPM at 20.44% is below both year-ago (22.36%) and the guided 'easing' commodity pressure — watch whether Q3 FY27 shows the promised margin relief.
W3
Effective tax rate normalised to ~24.9% this quarter from an abnormally low 1.2% a year ago (MAT-credit driven) — watch whether this becomes the stable base for H2 FY27 comparisons.
Auditor's consolidated review carries a qualified conclusion (one subsidiary + its two sub-subsidiaries, ₹83.57 Cr revenue/₹9.41 Cr PAT, not reviewed by any auditor — same qualification as Q1 FY27); no exceptional items this quarter for either statement; the standalone (-25.2% YoY PAT) vs consolidated (-1.9% YoY PAT) divergence is almost entirely a MAT-credit-utilisation tax-timing swing, not operating performance; Axiom Ayurveda (subsidiary w.e.f Apr 1, 2026) and IncNut Digital (w.e.f Jun 1, 2026) are newly consolidated, inflating YoY revenue/expense comparability.
Record revenue growth halted profit; strategic investments beating but margins squeezed
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat on revenue growth (+36%); missed on profit (down -1.9% YoY). Prior margin-recovery guidance was cautious but not met Q2.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong operational momentum (revenue +36%, strategic investments +73%) underpinned by domestic acceleration and successful new launches. However, PAT declined 1.9% YoY as gross margin compressed 520 bps from business mix integration and input costs. Margin recovery hinges on H2 input cost normalization and pricing stick; if it fails, profit growth stalls. Hold pending proof of H2 margin recovery.
₹1087.7 Cr
Revenue · +36.2% YoY₹145.5 Cr
Reported PAT · −1.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 36% to INR1,088 Cr
METDelivered 1087.7 Cr, +36.2% YoY — essentially exact match
Strategic investments grew 73% L2L; now ₹800+ Cr run-rate
METImplies Q2 run-rate ~₹200 Cr from Q1 base of ~₹160 Cr — pace consistent
Domestic sales grew 49%
METNot broken out in delivered result, but strategic investments 73% + core modest growth compatible
PAT lower by 3% YoY
METDelivered -1.9% YoY (145.5 Cr); call stated ~144 Cr − likely rounding variation
Gross margin moderated 520 bps; 400 bps from input costs
UnverifiedNPM compressed from prior year; not detailed in delivered result; claim unverified
H2 core business to grow 18–20%
METForward guidance; Q1 core was ~61% growth, H1 core down 12% due to GST/base
Earnings quality
What changed since the last call
Strategic investments guidance raised
UpgradeFrom ₹750–800 Cr range (Q1 guidance) to ₹800–850 Cr FY27 run-rate. Driven by Axiom, IncNut, Brillare momentum (73% L2L growth) beating 20–30% prior expectation.
Core business H2 guidance improved
UpgradeFrom vague 'accelerate beyond 6%' (prior) to specific 18–20% H2 growth guidance. Implies H1 core was weak (~12% down, GST timing) but recovery tracked.
International business status revised
NeutralQ2 declined 2% (vs prior guidance of 'recovery Q3–Q4'). October month now positive. Management remains on track for H2 recovery, but Q2 miss softens near-term confidence.
Margin recovery expectation
DowngradeGross margin down 520 bps vs prior claim that pressure would be 'temporary, offset by price increases.' H2 recovery now dependent on input cost deflation, not pricing — lower conviction.
The Q&A
Analysts pressed hard on margin recovery timelines, strategic investment profitability (Harit Kapoor, Arnab Mitra), and international turnaround credibility (Rahul Jha). Management mostly answered directly but deferred exact H2 margin targets and profitability runways. Defensiveness on core business decelerating (down 12% H1) was offset by confidence on H2 18–20% guide. Overall Q&A showed skepticism on near-term profit recovery; analysts were bullish on revenue but cautious on earnings.
New launches pricing — Abneesh Roy, Nuvama Securities
AnsweredKesh King Scalp at ₹500–1000 premium tier, e-com/modern trade focus. Maa (baby care) 25–50% cheaper than L'Orèal/Derma Co, mass market play.
Strategic investment profitability — Abneesh Roy, Nuvama Securities
PartialDhruv: All 4 brands growing >20%, 5% acceleration QoQ. Different levers, Axiom/TMC margins moving high-20s%. Growth strong; timeline withheld.
A&P spend intensity — Harit Kapoor, Investec
AnsweredA&P 18–19% max for full year. Pricing +5.5% YoY; passed through; rural mixed, but peak season now.
Core business H1 vs H2 — Arnab Mitra, Goldman Sachs
AnsweredH1 affected by GST/timing; H2 momentum continuing, 18–20% range expected. October positive.
Gross margin recovery — Arnab Mitra, Goldman Sachs
Partial~400 bps RM cost inflation, balance mix. H2 will benefit from procured supplies at current prices. Exact recovery % not given.
Strategic investment guidance — Rahul Jha, Bowhead
AnsweredDhruv: Will do ₹800+ Cr this year. Mohan: Keep at ₹800–850 Cr range.
International business constraints — Rahul Jha, Bowhead
AnsweredVivek: Limited India mfg model by design; mfg in BD, UAE, Germany. Iraq disruptions unique to us; moving through Port Aqaba now. Growth in most geos.
International turnaround timing — Saksham Tyagi, Desvelado
PartialVivek: Now in green post-Sept/Oct realignment. OTC goods curbed (2% of business); recovery trajectory continuing.
AI/data analytics progress — Saksham Tyagi, Desvelado
PartialManish: Ahead of schedule; completion Q3. Already seeing pilot results. Real gains Q3 onwards.
Guidance
Strategic investments FY27 ₹800–850 Cr run-rate (upgraded)
HighQ2 run-rate already ~₹200 Cr (implied); 4 brands tracking 20%+ growth; investments in capacity (Axiom, IncNut) ongoing
Core domestic H2 FY27 growth 18–20%
HighH1 core down 12% (GST timing, base); momentum resuming Q3. Skincare, hair, 7 Oils strong; pricing traction
International recovery Q3–Q4 FY27
MediumQ2 declined 2%; Oct month positive per mgmt; supply chain realignment ongoing; geopolitical headwinds (Iraq, Nepal, regional) gradually easing
Gross margin recovery H2 from input cost normalization
Medium400 bps of 520 bps hit from RM inflation. Mgmt procured supplies at current prices; expects benefit in H2. No specific margin target given; hedged on timing.
EBITDA margin sustenance via cost controls and pricing
MediumEBITDA grew 25% despite 520 bps gross margin compression; operating leverage demonstrated. A&P capped 18–19%; indicates operating margin pressure.
Strategic investment capex ongoing for Axiom, IncNut, QuickCom, AloFrut visibility
HighCapacity expansion underway (Axiom modern trade, IncNut marketplace); digital platform investment (AI/data analytics to complete Q3)
Risks the call surfaced
Margin compression
HighGross margin down 520 bps YoY (400 bps input inflation, 120 bps mix). Pricing +5.5% insufficient. H2 recovery dependent on input cost deflation, not pricing — limited pricing power in core segments.
International business volatility
MediumInternational revenue down 2% Q2 due to supply chain disruptions (Iraq, Nepal floods, regional conflicts). Recovery guidance Q3–Q4 not proven. Logistics constraints (goods movement, port disruptions) limit upside.
Strategic investment profitability
MediumAxiom, Brillare, IncNut, The Man Company grew 73% L2L but are in investment phase. Profitability recovery timeline vague. Margin contribution to consolidated result unclear; could pressure reported margins if losses mount.
Domestic core business deceleration
MediumCore business down 12% H1 (GST timing, low base). H2 guidance 18–20% recovery assumed but not yet delivered. Rural market weakness (rainfall/drought in pockets) pressures volume growth.
Execution risk on new launches
LowKesh King Scalp First, Maa, premium variants are new to market or new positioning. Premium pricing and e-com/modern trade focus may not scale to mass market; brand-building requires sustained A&P and distribution.
Management
Score 7/10. Clear on operational metrics and growth momentum; transparent on margin headwinds and input cost inflation. Deferred specifics on strategic investment profitability timelines and H2 exact margin recovery targets. Some hedging on international recovery timing. Beat on strategic investments (73% vs 20–30% guided). On track for core H2 guidance (18–20%). Missed on profit growth (PAT -1.9% YoY despite +36% revenue); blamed on transitory factors (input costs, tax normalization, integration). Cost controls demonstrated (25% EBITDA growth).
1 · Q3 FY27
Core business momentum expected 18–20% growth; margin recovery from input cost normalization
2 · Q3–Q4 FY27
International business turnaround; geopolitical constraints ease; alternate supply routes operational
3 · Q3 onwards
Data analytics and AI platform completion; digitization of supply chain, forecasting, D2C
Hold pending proof of H2 margin recovery.
The ₹36 Crore Revenue Miss That Hid a Profit Stall
Revenue surged 36% to ₹1,088 Cr, but net profit declined 1.9% to ₹146 Cr. The margin squeeze — 520 basis points — reveals a quarter of momentum without earnings lift. Management's margin-recovery bet hinges on input costs normalizing, not pricing power.
₹146 Cr
-1.9% YoY
₹222 Cr
+25% YoY
down 520 bps
YoY; input costs +400 bps, mix +120 bps
₹200+ Cr
+73% L2L; guidance raised to ₹800–850 Cr
The quarter reads as two stories stacked on top of each other. On the surface: record revenue growth, strategic investments crushing prior guidance, organized channels accelerating to 37% of domestic. Underneath: gross margin compressed 520 basis points, net profit fell despite 36% revenue growth, and operating leverage turned negative. The company beat on top line and investment momentum but missed on the bottom line, a reversal of the usual FMCG playbook.
Where the profit decline came from
Start with the margin math. Gross margin fell 520 basis points YoY. Of that, approximately 400 basis points came from raw material inflation — oils and minerals cost more. Another 120 basis points was mix: strategic investments (Axiom, Brillare, IncNut, The Man Company) grew 73% but carry lower margins than the core portfolio. Pricing action of +5.5% YoY was real but insufficient to offset. The company holds that this is transitory — input cost normalization in H2 will restore margin. That bet is unproven, and Q2 is evidence that pricing power in core segments is constrained.
Revenue grew 36% to ₹1,088 Cr
Delivered ₹1,087.7 Cr, +36.2% YoY
Exact match
Strategic investments grew 73% L2L to ~₹200 Cr Q2 run-rate
Consistent with Q1 base of ~₹160 Cr; all 4 brands (Axiom, Brillare, IncNut, TMC) tracking 20%+ growth
Supported
Domestic core sales grew 49%
Implied by strategic investments +73% and overall domestic acceleration; not explicitly broken out in result
Supported
Margin pressure is temporary and offset by pricing and cost controls
Gross margin down 520 bps; pricing +5.5% fell short. EBITDA +25% but NPM -1.9% shows cost controls are real but insufficient
Overstated — pricing power limited; margin recovery now depends on input cost deflation
H2 core business to grow 18–20%
Forward guidance; H1 core down 12% (GST timing, base effects); October positive per mgmt but unquantified
Supported (but requires proof)
What changed on this call
Strategic investments guidance raised from ₹750–800 Cr to ₹800–850 Cr FY27 run-rate
Core business H2 guidance became specific: 18–20% growth (previously vague 'accelerate beyond 6%')
Margin recovery timeline pushed to H2 and now depends on input cost normalization, not pricing leverage
International turnaround claim cited October month as positive, but no quantified recovery timeline confirmed
The street's read — price, flows, and the ownership lens
At ₹410.4 as of 9 November, the stock is trading neutral, above its 20- and 50-day simple moving averages (₹377.71 and ₹375.95 respectively) but below its 200-day average of ₹416.82. Year-to-date it has risen 14.9% off its 52-week low of ₹357.1, but remains 52.3% below its all-time high of ₹860. RSI at 69.7 reads as neutral (not overbought). The price action since the result announcement — not provided here — is the market's own verdict on whether the revenue beat offset the profit miss; the stock's neutral posture suggests the market is withholding judgment pending H2 execution.
Ownership has shifted modestly. FII holdings have contracted from 8.58% in FY2026 Q4 to 7.87% in FY2027 Q1, a decline of 71 basis points over the last quarter. DII holdings have drifted up slightly from 26.92% to 27.01%. Promoter stake remains locked at 54.84%, unchanged. The FII outflow is notable — it suggests international investors are trimming exposure, likely reflecting both the margin miss and the global risk-off sentiment in emerging markets. This is worth monitoring: if FII exits accelerate, the stock could face pressure even if H2 guidance is hit.
Bull and bear case
Revenue growth +36% and domestic +49%
positiveStrategic investments beat (73% vs 20–30% guided)
positiveOrganized channels accelerating to 37% of domestic
positiveNew launches traction (Kesh King Scalp, Maa, premium variants)
positiveEBITDA +25% shows cost control and operational resilience
positiveNet profit down 1.9% despite 36% revenue growth
negativeGross margin down 520 bps; pricing +5.5% insufficient to offset
negativeStrategic investments still in investment phase, profitability timeline vague
warnInternational business -2% Q2; Oct recovery unquantified
warnCore business H1 down 12%; H2 18–20% guidance is a reversal
warnMargin recovery dependent on input cost deflation, not pricing power
warnFII holdings down 71 bps this quarter; outflow signal
warnRisks, ranked by how much they should concern a holder
Margin recovery fails to materialize in H2
HighIf input costs don't normalize or remain sticky, the 520 bps margin hit will persist. With limited pricing power in core segments (rural, mass trade), profit growth will remain stalled. The stock has no margin of safety on earnings if H2 brings another surprise.
Strategic investments profitability timeline extends or margins disappoint
HighThese 4 brands are now ~26% of domestic revenue but contribution to consolidated profit is unclear. If they remain in investment phase longer than expected or their margin trajectory is weaker than early guidance, EBITDA leverage could disappoint in FY28. Guides said Axiom/TMC at 'high 20s%' margins but no consolidated bridge.
International business recovery unproven; geopolitical headwinds persist
MediumQ2 declined 2%, October is claimed positive but unquantified. Iraq, Nepal floods, and regional conflicts are cited as disruptions. If geopolitical risks don't ease or supply chain realignment takes longer, the recovery Q3–Q4 guidance could slip. This was 4–5% of revenue in prior years; a miss here is material.
Core business momentum unproven; H1 -12% is a setback
MediumH1 core was down 12% (GST timing cited). H2 guide of 18–20% is ambitious and a sharp reversal. If peak season (Diwali, year-end) doesn't drive the claimed momentum, or if rural markets remain under pressure (drought in pockets cited), the core growth will disappoint and drag overall results.
FII outflow accelerates; ownership shift to DIIs
MediumFII have trimmed from 8.58% to 7.87% in one quarter. If exits accelerate as margin concerns mount, the stock could face near-term selling pressure even if fundamentals stabilize. A 100+ bps FII outflow would be concerning and could drag valuation multiple.
Pricing power weaker than implied; competitive intensity in premium segments
Low-MediumPricing +5.5% YoY was insufficient to offset input cost inflation. New launches (Kesh King Scalp, Maa) face competition from L'Orèal, Derma Co, Mamaearth in premium. If competitive intensity forces pricing discipline, margin recovery narrative weakens.
What to watch next
1 · Q3 margin recovery — the acid test
The critical measure: gross margin in Q3. If input costs normalize and margin recovers 200–300 bps toward historical levels, the H2 guidance is credible. If margin stays compressed or deteriorates further, the profitability outlook is broken. Watch for management commentary on raw material pricing and procurement advantages.
2 · Core business H2 growth delivery — momentum vs. reality
H1 core was down 12%; H2 is guided 18–20%. October was called positive but unquantified. The next print will show whether peak season delivered the claimed acceleration. If core H2 comes in below 15%, the growth narrative for FY27 full year will need downgrade.
3 · Strategic investment profitability path — early signals of EBITDA contribution
Management's confidence on Axiom/TMC at 'high-20s%' margins is encouraging, but consolidated impact unclear. Q3 will show whether these brands are improving contribution or remaining in cash-burn mode. If aggregate strategic investment EBITDA margin trails expectations, the FY28 earnings model will need recalibration.
4 · International turnaround proof — October positive becomes quarter trend
October month is cited as positive, but it represents one data point. Q3 will show whether the recovery is sustained or a blip. Watch for quantified commentary on each geography and whether Iraq/Nepal disruptions have eased or persisted.
The number to track from here
This is not a step-change — this is a company in a transitional quarter where operational momentum (revenue +36%, strategic investments +73%) is real but profit growth is stalled by margin compression that management claims is temporary. The Q2 print was honest: top line surged, bottom line didn't, and margins took a 520 bps hit. Management's H2 margin recovery bet is credible in thesis but unproven in execution.
The single number to track from here is Q3 gross margin. If it recovers materially toward prior-year levels (at least 200 bps recovery), the H2 guidance is on track and the strategic investment narrative holds. If it stays compressed, profit growth stalls and the stock re-rates. The street is currently neutral; the outcome of Q3 margin will determine whether that shifts to Hold (margin recovery delivered) or Reduce (margin remains under pressure). The honest read is Hold: revenue momentum is real, but earnings proof deferred to H2.